--- title: "Pre-market hot trades in US stocks: Rocket Lab up 3.09% in pre-market, driven by favorable contracts and market enthusiasm, but valuation risks still need to be heeded" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/281179303.md" description: "Rocket Lab pre-market up 3.09%; Apellis Pharma pre-market up 139.56%; Hitek Global Inc. pre-market up 133.25%; Classover Holdings - Class B pre-market up 56.90%" datetime: "2026-03-31T11:37:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281179303.md) - [en](https://longbridge.com/en/news/281179303.md) - [zh-HK](https://longbridge.com/zh-HK/news/281179303.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/281179303.md) | [English](https://longbridge.com/en/news/281179303.md) # Pre-market hot trades in US stocks: Rocket Lab up 3.09% in pre-market, driven by favorable contracts and market enthusiasm, but valuation risks still need to be heeded **Pre-market Hot Trades in US Stocks** Rocket Lab is up 3.09% in pre-market trading. Based on recent key news: 1. On March 30, Rocket Lab announced a $190 million contract with the U.S. Department of Defense to execute 20 suborbital launch missions. This news led to a stock price drop of about 8%, as investors took a wait-and-see approach regarding the profit path. 2. On March 28, news of SpaceX's planned IPO sparked market enthusiasm for low Earth orbit satellite concept stocks, driving Rocket Lab's stock price up over 10%. 3. On March 28, Rocket Lab successfully executed its first dedicated launch mission for the European Space Agency, enhancing market confidence in its technical capabilities, resulting in a stock price increase. There is increased policy uncertainty in the commercial space sector, warranting caution. **Top Gainers in Pre-market US Stocks** Apellis Pharma is up 139.56% in pre-market trading. Based on recent key news: 1. On March 31, Biogen announced the acquisition of Apellis Pharmaceuticals for $5.6 billion, with an acquisition price of $41 per share, representing a premium of over 140% compared to Apellis' closing price on Monday. This news drove Apellis' stock price sharply higher in pre-market trading. 2. On March 31, through this acquisition, Biogen will gain two approved drugs from Apellis, which is expected to immediately boost its revenue. This move aligns with Biogen's strategy to expand in the fields of immunology and rare diseases. 3. On March 31, Apellis' Syfovre and Empaveli drugs achieved net sales of $689 million in 2025, with expected revenue growth in the mid-to-high single digits over the next few years. This financial outlook further strengthened market confidence in the acquisition, enhancing Biogen's competitiveness in the rare disease sector. Hitek Global Inc. is up 133.25% in pre-market trading. Based on recent key news: 1. On March 27, Hitek Global Inc. announced the sale of 100 million Class A shares to certain institutional investors at a price of $0.03 per share, with the transaction expected to close on March 30. This news attracted market attention, leading to stock price volatility. 2. On March 27, the company announced a $3 million registered direct offering pricing, demonstrating its commitment to business expansion, further driving the stock price up. 3. On March 27, Hitek Global Inc. announced the signing of a securities purchase agreement with specific entities in Xiamen, China, indicating the company's commitment to expanding its business in the technology sector, which enhanced market confidence. There is high market attention on the expansion of the technology industry. Classover Holdings is up 56.90% in pre-market trading. Based on recent key news: 1. On March 31, Classover Holdings re-complied with Nasdaq's minimum bid requirements. This news boosted market confidence and significantly drove up the stock price. Source: KIDZ Stock News 2. On March 30, Kidoz Inc. released relevant information through the EDGAR system to ensure information transparency and compliance. This move further stabilized investor sentiment and supported the rise in stock price. Source: Public Technologies The US stock market has been volatile recently, and investors should exercise caution ### 相關股票 - [Rocket Lab (RKLB.US)](https://longbridge.com/zh-HK/quote/RKLB.US.md) ## 相關資訊與研究 - [SpaceX files for blockbuster IPO confidentially, eyes $1.75 trn valuation](https://longbridge.com/zh-HK/news/281403247.md) - [SpaceX's $75 Billion IPO Draws Investor Focus](https://longbridge.com/zh-HK/news/281231695.md) - [Apellis Pharmaceuticals to be Acquired by Biogen in Merger](https://longbridge.com/zh-HK/news/281296670.md) - [Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout](https://longbridge.com/zh-HK/news/281350813.md) - [Biogen (BIIB) Valuation Check After Mixed Recent Share Returns And Pipeline Driven Undervaluation Narrative](https://longbridge.com/zh-HK/news/281163167.md)